sophieannasのブログ一覧

A colorless and transparent "beads", can let the blinding ocular fundusdisease to light. Recently, the State Food and Drug Administration issued a public notice, approval XinDa bio Pharmaceutical (Suzhou) Co., Ltd.Compaq Xipu ophthalmic injection for the treatment of wet age-related molecular biology degeneration, marking China's first treatment of senile macular degeneration of ocular fundus diseases in high-end bio medicine officially listed. It is reported, this medicine is also China's first global intellectual property monoclonal antibody drugs.

Bioabb specializing in the production of antibodies and customized services, to antibody platform as the core of the establishment of a series ofrelated technical platform and animal breeding base. We provide mAbproducts completed by perennial in the antibody production of professional staff, technical route of mature, stable and reliable product quality, save you personally prepared to spend time and energy. At the same timemonoclonal antibody production in every step of screening and verification of strict, provides the high quality for the customer the monoclonal antibody.

For more Bioabb antibody info , visit http://www.bioabb.com/categories/KIT/Elisa-Kit , more than 6000 antibodies products are available at this site .

Combined with our company itself has the kit development platform and diagnostic reagent R & D team, we can guarantee the most effectiveapplication of monoclonal antibody products in the field of detection. So far,this platform has been successfully prepared a variety of diagnostic reagentgrade monoclonal antibody on raw material, by the downstream customers . And recently , Bioabb put up many antibody promotion activities , and the regular clients can enjoy more discount , visit Bioabb website http://www.bioabb.com to get more promotion activities info .

A colorless and transparent "beads", can let the blinding ocular fundusdisease to light. Recently, the State Food and Drug Administration issued a public notice, approval XinDa bio Pharmaceutical (Suzhou) Co., Ltd.Compaq Xipu ophthalmic injection for the treatment of wet age-related molecular biology degeneration, marking China's first treatment of senile macular degeneration of ocular fundus diseases in high-end bio medicine officially listed. It is reported, this medicine is also China's first global intellectual property monoclonal antibody drugs.

Bioabb specializing in the production of antibodies and customized services, to antibody platform as the core of the establishment of a series ofrelated technical platform and animal breeding base. We provide mAbproducts completed by perennial in the antibody production of professional staff, technical route of mature, stable and reliable product quality, save you personally prepared to spend time and energy. At the same timemonoclonal antibody production in every step of screening and verification of strict, provides the high quality for the customer the monoclonal antibody.

For more Bioabb antibody info , visit http://www.bioabb.com/categories/KIT/Elisa-Kit , more than 6000 antibodies products are available at this site .

Combined with our company itself has the kit development platform and diagnostic reagent R & D team, we can guarantee the most effectiveapplication of monoclonal antibody products in the field of detection. So far,this platform has been successfully prepared a variety of diagnostic reagentgrade monoclonal antibody on raw material, by the downstream customers . And recently , Bioabb put up many antibody promotion activities , and the regular clients can enjoy more discount , visit Bioabb website http://www.bioabb.com to get more promotion activities info .

PCs are responsible for the production and secretion of antibody, the effector molecules of the humoral immune response. The molecular mechanisms responsible for vesicle docking and secretion implicated in the antibody-secretion process are not well-known, as they have not been studied, but it is known that SNARE proteins are responsible for many membrane-fusion processes in the cell. We show here that freshly isolated human colon LP-PCs and T-PCs from MM-PC patients and the U266 cell line, as a model for PC secretion, contain a set of these proteins.

SNAP23, STX3, and STX4 were localized mainly in the plasma membrane of PCs, and interactions of SNAP23 with STX3 and with STX4 were proven by IP. Interaction between SNAP23 and STX4 was also confirmed in situ. With the use of siRNA, as well as shRNA, the functional role of SNAP23, STX3, and STX4 in antibody secretion was also examined. The findings demonstrate that in addition to SNAP23, STX4 is implicated in the antibody secretion by a myeloma cell line and by normal human colon LP-PCs.

CUSABIO specializes in peptide production and customization service. Centering on antibody, we have established a series of technology platform and animal breeding base. The monoclonal antibodies are produced by professionals who work on antibody for many years. Cusabio peptide products have strong biological activity and they have wide applications . The Cusabio peptide products can be used to produce the drugs and many creams contain the peptide , which can reduce even elimination the wrinkles and the dark eyes circle . Visit http://www.cusabio.com/pro_27.html to choose the peptide products what you need .

In order to avoid destruction by the immune system, cancer cells play some small tools. When they split to form tumors, will avoid perceived macrophages, macrophages are engaged eliminate dead cells and dangerous invaders immune cells. Now, many cancer patients are treated using the antibody drug, some of these effects is to identify an antibody drug of tumor cells to allow the macrophages to destroy them. Although these drugs can prolong the lives of patients, but they are not always very effective - in part because cancer cells to immune cells by sending a "do not eat me" signal to fight back.

Now, researchers have devised in mice a small protein, it can cut off the signal, and can greatly improve the effectiveness of the antibody drug to the tumor to shrink. Stem cell biologist at Stanford University in Palo Alto, Calif. The Irving Weissman has been studying the spread of a charge of "Do not eat me" protein signal. The protein, called CD47, which protects cancer cells from leukemia cells and other macrophage phagocytosis. Last year, the research team reported Weissman said, a blocking CD47 antibody in tumor cells can stimulate macrophages to destroy tumors in mice. California Institute for Regenerative Medicine will provide $ 20 million fund in the near future for this anti-CD47 antibody testing in humans safety.

Although this method has potential, but this antibody also has certain disadvantages - the relatively large size limits their ability to penetrate tumors. In addition, they exist side effects, so the team Weissman Christopher Garcia and structural biologist at Stanford University in the laboratory of co-blocking CD47 tested another way. Garcia's team and Weissman recently in the journal "Science" describes the online version of their new research.

Bioabb specializes in antibody production and customization service. Centering on antibody, we have established a series of technology platform and animal breeding base. The monoclonal antibodies are produced by professionals who work on antibody for many years. You can visit this site http://www.bioabb.com/categories/Antibody/ to see more antibody info of the antibody benefits and the price of Bioabb. Our mature technical route and reliable quality will save your produce time and energy. We can provide customers with high-quality monoclonal antibody products by screening and verifying every production step strictly.

The researchers found a kind of monoclonal antibody which can into the internal of cancer cell effectively. This has long been a key goal of the development of important anti-cancer drugs, because most of the carcinogenic or cancer-related protein in cancer cells are hidden. Scientists making this new human monoclonal antibody, which are able to target a associated with a variety of types of cancer, cancer researchers have a great interest in the protein. Unlike other human therapeutic monoclonal antibodies only to the target cancer cells outside the protein, this is called ESK1 novel monoclonal antibodies capable of targeting a present in the protein in the cells.

ESK1 targeted is a referred to as a WT1 protein, which are overexpressed in many leukemia and other types of cancer including myeloma, breast cancer, ovarian cancer, and colorectal. WT1 is a preferred target for cancer drugs, not only because it is a kind of support to cancer formation of carcinogenic protein. And it only exists in unhealthy cells, WT1 targeted drug less likely to cause side effects. The researchers designed ESK1, in order to simulate an important component of the immune system, a T-cell receptor function.

T cell has a receptor system for identification of intracellular proteins. As the intracellular protein decomposition is a part of the process of the conventional cell, called the HLA molecules will be fragments of these proteins (referred to as a peptide) to the surface. When the T cells recognized the anomaly of certain peptides, T cells will kill the diseased cells. In the current study about monoclonal antibody, the researchers confirmed the only ESK1 be able to recognize the WT1 peptide, killing cancer cells in vitro as well as two different human mouse model of leukemia types. The researchers were surprised to find that antibodies capable of their own function.

We originally thought that there might need to take advantage of this antibody as a carrier to pass a drug or combination of radiation therapy to kill cancer cells, but the results show that these necessary. For more useful info , visit http://www.cusabio.com/product-101953/